# Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

> **NCT02988817** · PHASE1,PHASE2 · COMPLETED · sponsor: **Genmab** · enrollment: 306 (actual)

## Conditions studied

- Ovarian Cancer
- Cervical Cancer
- Endometrial Cancer
- Non Small Cell Lung Cancer (NSCLC)
- Thyroid Cancer
- Melanoma
- Sarcoma
- Solid Tumors

## Interventions

- **BIOLOGICAL:** Enapotamab vedotin (HuMax-AXL-ADC)

## Key facts

- **NCT ID:** NCT02988817
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-23
- **Primary completion:** 2021-11-12
- **Final completion:** 2021-11-12
- **Target enrollment:** 306 (ACTUAL)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02988817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02988817, "Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02988817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*